Tags

Type your tag names separated by a space and hit enter

Preparedness of European diagnostic microbiology labs for detection of SARS-CoV-2, March 2020.
J Clin Virol. 2020 07; 128:104432.JC

Abstract

BACKGROUND

To track the European spread of SARS-CoV-2, decentralized testing became necessary and test capacity needed to be expanded outside reference laboratories rapidly.

METHODS

We assessed via an online questionnaire the preparedness of European hospital laboratories for detection of SARS-CoV-2 and listed the main drawbacks for implementation.

RESULTS

Forty-five percent of the surveyed labs had a test in place by March 26th which is well into the first wave of the pandemic in most countries.

CONCLUSIONS

The main implementation barriers for introduction of a SARSCoV-2 molecular assay in European diagnostic laboratories were availability of positive controls and a specificity panel.

Authors+Show Affiliations

Department of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Wilrijk, Belgium; Department of Microbiology, University Hospital Antwerp, Edegem, Belgium. Electronic address: veerle.matheeussen@uza.be.Department of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Wilrijk, Belgium; Department of Microbiology, University Hospital Antwerp, Edegem, Belgium.Department of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Wilrijk, Belgium.Department of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Wilrijk, Belgium.Viroscience Department, Erasmus MC, Rotterdam, the Netherlands.Department of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Wilrijk, Belgium; Department of Microbiology, University Hospital Antwerp, Edegem, Belgium.Department of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Wilrijk, Belgium.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32422569

Citation

Matheeussen, Veerle, et al. "Preparedness of European Diagnostic Microbiology Labs for Detection of SARS-CoV-2, March 2020." Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology, vol. 128, 2020, p. 104432.
Matheeussen V, Loens K, Lammens C, et al. Preparedness of European diagnostic microbiology labs for detection of SARS-CoV-2, March 2020. J Clin Virol. 2020;128:104432.
Matheeussen, V., Loens, K., Lammens, C., Vilken, T., Koopmans, M., Goossens, H., & Ieven, M. (2020). Preparedness of European diagnostic microbiology labs for detection of SARS-CoV-2, March 2020. Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology, 128, 104432. https://doi.org/10.1016/j.jcv.2020.104432
Matheeussen V, et al. Preparedness of European Diagnostic Microbiology Labs for Detection of SARS-CoV-2, March 2020. J Clin Virol. 2020;128:104432. PubMed PMID: 32422569.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Preparedness of European diagnostic microbiology labs for detection of SARS-CoV-2, March 2020. AU - Matheeussen,Veerle, AU - Loens,Katherine, AU - Lammens,Christine, AU - Vilken,Tuba, AU - Koopmans,Marion, AU - Goossens,Herman, AU - Ieven,Margareta, AU - ,, Y1 - 2020/05/15/ PY - 2020/05/05/received PY - 2020/05/09/accepted PY - 2020/5/19/pubmed PY - 2020/7/7/medline PY - 2020/5/19/entrez KW - COVID KW - Molecular test KW - Pandemic KW - SARS-CoV-2 SP - 104432 EP - 104432 JF - Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology JO - J Clin Virol VL - 128 N2 - BACKGROUND: To track the European spread of SARS-CoV-2, decentralized testing became necessary and test capacity needed to be expanded outside reference laboratories rapidly. METHODS: We assessed via an online questionnaire the preparedness of European hospital laboratories for detection of SARS-CoV-2 and listed the main drawbacks for implementation. RESULTS: Forty-five percent of the surveyed labs had a test in place by March 26th which is well into the first wave of the pandemic in most countries. CONCLUSIONS: The main implementation barriers for introduction of a SARSCoV-2 molecular assay in European diagnostic laboratories were availability of positive controls and a specificity panel. SN - 1873-5967 UR - https://www.unboundmedicine.com/medline/citation/32422569/Preparedness_of_European_diagnostic_microbiology_labs_for_detection_of_SARS_CoV_2_March_2020_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1386-6532(20)30174-8 DB - PRIME DP - Unbound Medicine ER -